SWITZERLAND – Roche has announced a collaboration with Ibex Medical Analytics, an Israeli artificial intelligence-based cancer diagnostics startup to develop artificial intelligence assisted cancer detection device to help diagnose early cancer detection.
The companies will collaborate to create an embedded image analysis workflow for pathologists to use the cloud version of Roche’s uPath enterprise software to access Ibex’s AI algorithms, insights, and decision support tools.
The US Food and Drug Administration recently granted Breakthrough Device Designation to Ibex’s Galen platform, which is CE marked in Europe for breast and prostate cancer detection.
Customers using Roche Digital Pathology will gain access to Ibex’s innovative tools, such as algorithms that analyze prostate and breast biopsies, as a result of this collaboration.
Pathologists will be able to provide accurate, efficient, and timely diagnoses for their patients thanks to AI algorithms and digital workflows that will assist them in the detection and grading of cancer, identification of important non-cancerous features, case reporting, and other tasks.
“With the addition of Ibex’s clinical-grade image analysis tools to our NAVIFY Digital Pathology menu, we can aid pathologists and providers in delivering value-based patient care by increasing their efficiency and accuracy for higher quality cancer diagnosis,” said Jill German, Head of Roche Diagnostics Pathology Customer Area.
Roche provides a complete digital pathology solution, from tissue staining to the generation of high-quality digital images that can be evaluated using automated clinical image analysis algorithms.
Pathologists will be able to provide accurate, efficient, and timely diagnoses for their patients thanks to the clinical-grade AI algorithms and digital workflows included in this expanded menu of tools, which will assist them in the detection and grading of cancer, identification of important non-cancerous features, case reporting, and more.
“Digital pathology provides the capability to introduce new, innovative ways for laboratories to improve quality and efficiency of cancer diagnosis,” said Joseph Mossel, who serves as co-founder and CEO of Ibex Medical Analytics.
“Together with Roche, we look forward to transforming pathology by delivering powerful AI-based tools to the fingertips of pathologists.”
Just recently, Netherland’s based Royal Philips launched Its Digital Pathology Suite-IntelliSite- a comprehensive, scalable suite of software tools and capabilities designed to help streamline workflows, improve cancer diagnosis, and increase pathology lab efficiency.
The partnership between Roche and Ibex Medical Analytics will prove vital as pathology is beginning to transition to a digital discipline that will aid, streamline and improve diagnoses and clinical decision-making.
Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE
